SCNN1A and acute respiratory distress syndrome: Importantly, NDUFS1 is well-known to convert NADH into NAD+ while accumulation of NAD+ in pulmonary epithelial cells by treatment with Olaparib, the clinical available PARP inhibitor promotion of NAD+ accumulation, normalized the reduced expression of ENaCα and lung damage during ALI.